| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:1598.)
© 2001 American Heart Association, Inc.
Original Contributions |
Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies
Stroke Therapy Academic Industry Roundtable II (STAIR-II)Correspondence and reprint requests to Marc Fisher, MD, UMass/Memorial Health Care, 119 Belmont St, Worcester, MA 01605. E-mail fisherm{at}ummhc.org
Abstract—The development of therapies for acute ischemic stroke has achieved a few notable successes and, unfortunately, many unsuccessful efforts. Many valuable lessons for the future assessment of new acute stroke therapies can be gleaned from the positive and negative prior trials. Phase I and II trials must be carefully designed and implemented to derive relevant, valuable information needed to proceed to phase III trials with promising interventions. The phase III trial should evaluate drug efficacy in an appropriately targeted stroke population evaluated by a meaningful and reliable outcome measure. Combinations of various types of stroke therapies will likely be increasingly assessed in future trials that are designed and implemented by cooperative efforts between the pharmaceutical industry, government agencies, academic advisors and clinical investigators. The chances for future success in demonstrating efficacy with acute stroke therapies will be enhanced by carefully conceived, scientifically based clinical trials. The recommendations contained in this document may help to focus attention on how to achieve the goal of developing an expanding number of a effective and safe acute stroke therapies.
Key Words: clinical trials • stroke, acute • therapy
This article has been cited by other articles:
 |
|
 |
|
  M. S. Hussain and A. Shuaib Research Into Neuroprotection Must Continue ... but With a Different Approach Stroke, February 1, 2008; 39(2): 521 - 522. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan The 2007 Feinberg Lecture: A New Road Map for Neuroprotection Stroke, January 1, 2008; 39(1): 242 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Kelly, J. D. Morrow, M. Ning, W. Koroshetz, E. H. Lo, E. Terry, G. L. Milne, J. Hubbard, H. Lee, E. Stevenson, et al. Oxidative Stress and Matrix Metalloproteinase-9 in Acute Ischemic Stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) Study Stroke, January 1, 2008; 39(1): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Savitz, R. Lew, E. Bluhmki, W. Hacke, and M. Fisher Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials Stroke, December 1, 2007; 38(12): 3205 - 3212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials Stroke, November 1, 2007; 38(11): 3055 - 3062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shuaib, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, H.-C. Diener, T. Ashwood, W. W. Wasiewski, U. Emeribe, et al. NXY-059 for the Treatment of Acute Ischemic Stroke N. Engl. J. Med., August 9, 2007; 357(6): 562 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Boyd, C. O. Weiss, J. Halter, K. C. Han, W. B. Ershler, and L. P. Fried Framework for Evaluating Disease Severity Measures in Older Adults With Comorbidity J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 286 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Goldberg New Approaches to Clinical Trials in Neuroprotection: Introduction Stroke, February 1, 2007; 38(2): 789 - 790. [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, D. F. Hanley, G. Howard, E. C. Jauch, S. Warach, and for the STAIR Group Recommendations From the STAIR V Meeting on Acute Stroke Trials, Technology and Outcomes Stroke, February 1, 2007; 38(2): 245 - 248. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg, M. D. Hill, Y. Y. Palesch, K. J. Ryckborst, and D. Tamariz The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--I: Physiological Responses and Safety Results Stroke, August 1, 2006; 37(8): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, J. A. Zivin, T. Ashwood, A. Davalos, S. M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, H.-G. Hardemark, et al. NXY-059 for Acute Ischemic Stroke N. Engl. J. Med., February 9, 2006; 354(6): 588 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher and for the Stroke Therapy Academic Industry Roundtabl Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable Stroke, August 1, 2005; 36(8): 1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Foerch, O. C. Singer, T. Neumann-Haefelin, R. du Mesnil de Rochemont, H. Steinmetz, and M. Sitzer Evaluation of Serum S100B as a Surrogate Marker for Long-term Outcome and Infarct Volume in Acute Middle Cerebral Artery Infarction Arch Neurol, July 1, 2005; 62(7): 1130 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Weir, M. Kaste, K. R. Lees, and for the Glycine Antagonist in Neuroprotection Int Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy Stroke, September 1, 2004; 35(9): 2111 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Macleod, T. O'Collins, D. W. Howells, and G. A. Donnan Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias Stroke, May 1, 2004; 35(5): 1203 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sughrue, E. S. Connolly Jr, M. Krams, K. R. Lees, W. Hacke, A. P. Grieve, J.-M. Orgogozo, and G. A. Ford Effectively Bridging the Preclinical/Clinical Gap: The Results of the ASTIN Trial * Response Stroke, April 1, 2004; 35(4): e81 - e82. [Full Text] [PDF]
|
|
|
|
|
|
F. B. Young, K. R. Lees, and C. J. Weir Strengthening Acute Stroke Trials Through Optimal Use of Disability End Points Stroke, November 1, 2003; 34(11): 2676 - 2680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Donnan, S. M. Davis, and M. Kaste Recommendations for the Relationship Between Sponsors and Investigators in the Design and Conduct of Clinical Stroke Trials Stroke, April 1, 2003; 34(4): 1041 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, G. W. Albers, K. J. Becker, and D. L. Tirschwell Patient Safety in Trials of Therapy for Acute Ischemic Stroke JAMA, February 27, 2002; 287(8): 987 - 987. [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lyden, P. Bath, M. Fisher, and B. C. Tilley Systematic Review of Nimodipine Systematic Review of Nimodipine: Re: Stroke Therapy Academic Industry Roundtable II (STAIR-II) : Re: Stroke Therapy Academic Industry Roundtable II (STAIR-II) Stroke, February 1, 2002; 33(2): 639 - 640. [Full Text] [PDF]
|
|
|
|
 |
|
 J. McCulloch and D. Dewar A radical approach to stroke therapy PNAS, September 25, 2001; 98(20): 10989 - 10991. [Full Text] [PDF]
|
|